Sernova’s Cell Pouch Shows Long-Term Efficacy in Diabetes

Sernova (TSE:SVA) has released an update.

Sernova Corp’s Phase I/II clinical trial shows promising results with their Cell Pouch system successfully enabling sustained insulin independence in patients with type 1 diabetes, with healthy, functioning islets seen more than five years post-transplant. The new data, indicating no detrimental tissue effects and the potential for a functional cure, brings hope to those affected by the disease.

For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.